Effect of N-methyl-D-aspartate (NMDA) receptor antagonists on α-synuclein-evoked neuronal nitric oxide synthase activation in the rat brain

Pharmacological Reports

Volumn 61, Issue 6, 2009, Pages 1078-1085

  Adamczyk, Agata ^a   Czapski, Grzegorz A ^a   Kaźmierczak, Anna ^a   Strosznajder, Joanna B ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

APV; MK 801; NAC peptide; Nitric oxide synthase; NMDA receptor; synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMINO 5 PHOSPHONOPENTANOATE; AMINO 5 PHOSPHONOVALERIC ACID; DIZOCILPINE; DNA; LIPID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURONAL NITRIC OXIDE SYNTHASE; PEROXYNITRITE; PROTEIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; NERVE CELL; NONHUMAN; RADIOASSAY; RAT;

EID: 76049122436     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70170-7     Document Type: Article

References (45)

1. Adamczyk A, Czapski GA, Jȩœko H, Strosznajder RP: Non-Aβ component of Alzheimer's disease amyloid and amyloid beta peptides evoked poly(ADP-ribose) polymerase-dependent release of apoptosis-inducing factor from rat brain mitochondria. J Physiol Pharmacol, 2005, 56, Suppl 2, 5-13.
2. Adamczyk A, Kacprzak M, Kaźmierczak A: Alphasynuclein decreases arachidonic acid incorporation into rat striatal synaptoneurosomes. Folia Neuropathol, 2007, 45, 230-235.
3. Adamczyk A, Kaźmierczak A, Strosznajder JB: α-Synuclein and its neurotoxic fragment inhibit dopamine uptake into rat striatal synaptosomes. Relationship to nitric oxide. Neurochem Int, 2006, 49, 407-412.
4. 2+ channels. Neuroreport, 2006, 7, 1883-1886.
5. Amer DA, Irvine GB, El-Agnaf OM: Inhibitors of α-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp Brain Res, 2006, 173, 223-233.
6. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR: Role of nitric oxide synthases in Parkinson's disease: A review on the antioxidant and anti-inflammatory activity of polyphenols. Neurochem Res, 2008, 33, 2416-2426.
7. 45Ca uptake by rat brain microvesicles. Neurochem Res, 1994, 19, 1515-20.
8. Bodles AM, Guthrie DJ, Harriott P, Campbell P, Irvine GB: Toxicity of non-Aβ component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β-sheet structure and fibrils. Eur J Biochem, 2000, 267, 2186-2194.
9. Bojarski L, Herms J, Kuźnicki J: Calcium dysregulation in Alzheimer's disease. Neurochem Int, 2008, 52, 621-633.
10. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, Zaccheo D, Abbruzzese G, Tabaton M: Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett, 2000, 287, 65-67.
11. Casley CS, Lakics V, Lee HG, Broad LM, Day TA, Cluett T, Smith MAet al.: Up-regulation of astrocyte metabotropic glutamate receptor 5 by amyloid-β peptide. Brain Res, 2009, 1260, 65-75.
12. Chalimoniuk M, Lukaćova N, Marsala J, Langfort J: Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuroscience, 2006, 141, 1033-1046.
13. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM: S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science, 2004, 304, 1328-1331.
14. Cookson MR: α-Synuclein and neuronal cell death. Mol Neurodegener, 2009, 4, 9.
15. Czapski GA, Cakala M, Chalimoniuk M, Gajkowska B, Strosznajder JB: Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J Neurosci Res, 2007, 85, 1694-1703.
16. Ebadi M, Sharma SK: Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal, 2003, 5, 319-335.
17. El-Agnaf OM, Irvine GB: Aggregation and neurotoxicity of α-synuclein and related peptides. Biochem Soc Trans, 2002, 30, 559-565.
18. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D: Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J, 2006, 20, 419-425.
19. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos, H et al.: Oxidative damage linked to neurodegeneration by selective α-Synuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
20. 15N] nitrate in biological fluids. Anal Biochem, 1982, 126, 131-138.
21. Harkany T, Mulder J, Sasvári M, Abrahám I, Kónya C, Zarándi M, Penke B et al.: N-Methyl-D-aspartate receptor antagonist MK-801 and radical scavengers protect cholinergic nucleus basalis neurons against β-amyloid neurotoxicity. Neurobiol Dis, 1999, 6, 109-121.
22. +-evoked glutamate release from adult rat hippocampal slices. Neurobiol Aging, doi: 10.1016/j.neurobiolaging.2008.08.009.
23. Kaźmierczak A, Strosznajder JB, Adamczyk A: α-Synuclein enhances secretion and toxicity of amyloid beta peptides in PC 12 cells. Neurochem Int, 2008, 53, 263-269.
24. Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of α-synuclein and its aggregates. J Neurosci, 2005, 25, 6016-6024.
25. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ: Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int J Biochem Cell Biol, 2008, 40, 1835-1849.
26. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, Huh K: The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm, 2006, 113, 1435-1439.
27. Lee SJ: Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J Mol Neurosci, 2008, 34, 17-22.
28. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D: Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron, 2009, 62, 788-801.
29. Lipton SA: Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov, 2006, 5, 160-170.
30. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G: Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1-40). Brain Res, 2002, 958, 210-221.
31. Norris EH, Giasson BI, Lee VM: α-Synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol, 2004, 60, 17-54.
32. Pákáski M, Kálmán J: Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int, 2008, 53, 103-111.
33. Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P: Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci, 2008, 65, 1272-1284.
34. 2+ increase in primary neuronal cells. J Biol Chem, 2008, 31, 29950-29960.
35. Schulz J, Matthews R, Klockgether T, Dichgans J, Beal M: The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative disease. Mol Cell Biochem, 1997, 174, 193-197.
36. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH et al.: α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J, 2002, 16, 1826-1828.
37. Sidhu A, Wersinger C, Vernier P: Does α-Synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J, 2004, 18, 637-647.
38. Song MS, Rauw G, Baker GB, Kar S. Memantine protects rat cortical cultured neurons against β-amyloid - induced toxicity by attenuating tau phosphorylation. Eur J Neurosci, 2008, 28, 1989-2002.
39. Stepanichev MY, Onufriev MV, Yakovlev AA, Khrenov AI, Peregud DI, Vorontsova ON, Lazareva NA, Gulyaeva NV: Amyloid-β (25-35) increases activity of neuronal NO-synthase in rat brain. Neurochem Int, 2008, 52, 1114-1124.
40. 1B1D receptor agonists abolish NMDA receptorevoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices. Cephalalgia, 1999, 19, 859-65.
41. Sung JY, Park SM, Lee CH, Um JW, Lee HJ, Kim J, Oh YJ et al.: Proteolytic cleavage of extracellular secreted α-Synuclein via matrix metalloproteinases. J Biol Chem, 2005, 280, 25216-25224.
42. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, Qureshi MM, Locascio JJ et al.: Decreased α-Synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun, 2006, 349, 162-166.
43. Watanabe Y, Kato H, Araki T: Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab Brain Dis, 2008, 23, 51-69.
44. Wersinger C, Prou D, Vernier P, Sidhu A: Modulation of dopamine transporter function by α-Synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J, 2003, 17, 2151-2153.
45. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA et al.: Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci USA, 2004, 101, 10810-10814.